Literature DB >> 21420154

Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy.

Christopher J Weight1, Casey Lythgoe, Raman Unnikrishnan, Brian R Lane, Steven C Campbell, Amr F Fergany.   

Abstract

OBJECTIVE: To compare survival in patients with clinical T1b renal tumors that are pathologically upstaged, or high-grade tumors, treated by either partial nephrectomy (PN) or radical nephrectomy (RN). The American Urological Association Guidelines recently advocated increasing use of PN in all patients with cT1 renal masses, but urologists are often hesitant to perform PN for larger more aggressive appearing cT1 renal tumors for fear of pathologic upstaging and a perceived compromise in cancer control.
METHODS: From a single institutional kidney cancer registry, 2511 consecutive patients with presumed cT1 renal cell cancer underwent extirpative surgery; 1981 (79%) were found to have renal cell cancer (RCC) and 213 (10.7%) were upstaged on final pathology. In addition, 95 (5%) were found to have grade 4 cancer. Cancer-specific survival (CS) and overall survival (OS) were compared between the groups.
RESULTS: In the upstaged cohort, patients treated by PN (n = 96, 45%) had comparable OS and CS when studied stage for stage with those treated by RN (n = 117, 55%). Multivariate cox-proportional hazards analysis of OS in the upstaged subset demonstrated that only age, grade, and Charlson score predicted OS, whereas PN vs RN and stage did not. PN did not compromise survival in patients with grade 4 RCC compared with RN.
CONCLUSIONS: PN does not appear to compromise the chance for cancer cure in patients with cT1 tumors that are upstaged pathologically to pT2 or pT3 or high-grade renal masses when compared with RN. These concerns should not deter a surgeon from attempting PN when otherwise technically feasible.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21420154     DOI: 10.1016/j.urology.2010.11.058

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

Review 1.  [Renal cell carcinoma: what is new in 2010?].

Authors:  I Tsaur; A Haferkamp
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors.

Authors:  Pascal Mouracade; Onder Kara; Julien Dagenais; M J Maurice; R J Nelson; Ercan Malkoc; J H Kaouk
Journal:  World J Urol       Date:  2017-02-14       Impact factor: 4.226

3.  Prevalence of baseline chronic kidney disease in 2,769 Chinese patients with renal cancer: nephron-sparing treatment is still underutilized.

Authors:  Kai-wei Yang; Geng-yan Xiong; Xue-song Li; Yuan Tang; Qi Tang; Cui-jian Zhang; Zhi-song He; Li-qun Zhou
Journal:  World J Urol       Date:  2014-08       Impact factor: 4.226

4.  Survival after partial and radical nephrectomy for high-risk disease: A propensity-matched comparison.

Authors:  Matthew J Maurice; Hui Zhu; Simon Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

Review 5.  Partial nephrectomy versus radical nephrectomy for clinical localised renal masses.

Authors:  Frank Kunath; Stefanie Schmidt; Laura-Maria Krabbe; Arkadiusz Miernik; Philipp Dahm; Anne Cleves; Mario Walther; Nils Kroeger
Journal:  Cochrane Database Syst Rev       Date:  2017-05-09

Review 6.  Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.

Authors:  Phillip M Pierorazio; Michael H Johnson; Hiten D Patel; Stephen M Sozio; Ritu Sharma; Emmanuel Iyoha; Eric B Bass; Mohamad E Allaf
Journal:  J Urol       Date:  2016-05-06       Impact factor: 7.450

7.  Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort.

Authors:  Jasmir G Nayak; Premal Patel; Jennifer Bjazevic; Zhihui Liu; Olli Saarela; Anil Kapoor; Ricardo Rendon; Jun Kawakami; Simon Tanguay; Rodney H Breau; Peter C Black; Darrel E Drachenberg
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

8.  Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis.

Authors:  Rebecca L O'Malley; Matthew H Hayn; Katherine A Brewer; Willie Underwood; Nicholas J Hellenthal; Hyung L Kim; Igor Sorokin; Thomas Schwaab
Journal:  World J Urol       Date:  2015-03-25       Impact factor: 4.226

9.  Identification of underserved areas for urologic cancer care.

Authors:  Matthew Mossanen; Jason Izard; Jonathan L Wright; Jonathan D Harper; Michael P Porter; Kenn B Daratha; Sarah K Holt; John L Gore
Journal:  Cancer       Date:  2014-02-12       Impact factor: 6.860

10.  Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.

Authors:  Amanda Ghanie; Margaret K Formica; Dongliang Wang; Gennady Bratslavsky; Telisa Stewart
Journal:  Int Urol Nephrol       Date:  2017-12-15       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.